<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
November 9, 2000
----------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-15190 13-3159796
-------------- ------------ ------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
106 CHARLES LINDBERGH BOULEVARD
UNIONDALE, NY 11553
----------------------------------
(Address of principal executive offices)
(516) 222-0023
----------------------------
(Registrant's telephone number, including area code)
<PAGE> 2
ITEM 5. OTHER EVENTS
On November 9, 2000 OSI Pharmaceuticals, Inc., a Delaware corporation
(the "Company") announced updated findings from two ongoing clinical studies of
the Company's lead anti-cancer drug candidate, OSI-774, as a single agent. The
data was communicated by investigators at the European Organization for the
Research and Treatment of Cancer symposium on new drugs in cancer therapy in
Amsterdam. Detailed information regarding the findings were released by the
Company in a press release on November 9, 2000 attached as an exhibit hereto and
incorporated by reference herein.
ITEM 7. EXHIBITS
--------------------------------------------------------------------------------
EXHIBIT NO. DESCRIPTION
--------------------------------------------------------------------------------
99 Press release, dated November 9, 2000
--------------------------------------------------------------------------------
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: November 9, 2000 OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
-----------------------------------------
Name: Robert L. Van Nostrand
Title: Vice President and Chief Financial
Officer, Secretary and Treasurer
<PAGE> 4
EXHIBIT INDEX
--------------------------------------------------------------------------------
EXHIBIT NO. DESCRIPTION
--------------------------------------------------------------------------------
99 Press release, dated November 9, 2000.
--------------------------------------------------------------------------------
